Literature DB >> 19615340

DNA ligase IV as a new molecular target for temozolomide.

Natsuko Kondo1, Akihisa Takahashi, Eiichiro Mori, Ken Ohnishi, Peter J McKinnon, Toshisuke Sakaki, Hiroyuki Nakase, Takeo Ohnishi.   

Abstract

Temozolomide (TMZ) is a methylating agent used in chemotherapy against glioblastoma. This work was designed to clarify details in repair pathways acting to remove DNA double-strand breaks (DSBs) induced by TMZ. Cultured mouse embryonic fibroblasts were used which were deficient in DSB repair genes such as homologous recombination repair-related genes X-ray repair cross-complementing group 2 (XRCC2)and radiation sensitive mutant54 (Rad54), non-homologous end joining repair-related gene DNAligase IV (Lig4). Cell sensitivity to drug treatments was assessed using colony forming assays. The most effective molecular target which was correlated with TMZ cell sensitivity was Lig4. In addition, it was found that small interference RNAs (siRNA) for Lig4 efficiently enhanced cell lethality induced by TMZ in human glioblastoma A172 cells. These findings suggest that down regulation of Lig4 might provide a useful tool for cell sensitization during TMZ chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19615340      PMCID: PMC2831288          DOI: 10.1016/j.bbrc.2009.07.045

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  46 in total

1.  Response to RAG-mediated VDJ cleavage by NBS1 and gamma-H2AX.

Authors:  H T Chen; A Bhandoola; M J Difilippantonio; J Zhu; M J Brown; X Tai; E P Rogakou; T M Brotz; W M Bonner; T Ried; A Nussenzweig
Journal:  Science       Date:  2000-12-08       Impact factor: 47.728

2.  Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent.

Authors:  K Ochs; B Kaina
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

3.  A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage.

Authors:  T T Paull; E P Rogakou; V Yamazaki; C U Kirchgessner; M Gellert; W M Bonner
Journal:  Curr Biol       Date:  2000 Jul 27-Aug 10       Impact factor: 10.834

4.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.

Authors:  W K Yung; M D Prados; R Yaya-Tur; S S Rosenfeld; M Brada; H S Friedman; R Albright; J Olson; S M Chang; A M O'Neill; A H Friedman; J Bruner; N Yue; M Dugan; S Zaknoen; V A Levin
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

5.  DNA damage recognition proteins localize along heavy ion induced tracks in the cell nucleus.

Authors:  Akihisa Takahashi; Nobuhiro Yamakawa; Tadaaki Kirita; Katsunori Omori; Noriaki Ishioka; Yoshiya Furusawa; Eiichiro Mori; Ken Ohnishi; Takeo Ohnishi
Journal:  J Radiat Res       Date:  2008-11-06       Impact factor: 2.724

6.  Low levels of DNA ligases III and IV sufficient for effective NHEJ.

Authors:  Frank Windhofer; Wenqi Wu; George Iliakis
Journal:  J Cell Physiol       Date:  2007-11       Impact factor: 6.384

7.  Effective enhancement of X-ray-induced apoptosis in human cancer cells with mutated p53 by siRNA targeting XIAP.

Authors:  Ken Ohnishi; Yoko Nagata; Akihisa Takahashi; Shigeki Taniguchi; Takeo Ohnishi
Journal:  Oncol Rep       Date:  2008-07       Impact factor: 3.906

8.  Association of DNA polymerase mu (pol mu) with Ku and ligase IV: role for pol mu in end-joining double-strand break repair.

Authors:  Kiran N Mahajan; Stephanie A Nick McElhinny; Beverly S Mitchell; Dale A Ramsden
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

9.  Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs.

Authors:  Wynand P Roos; Teodora Nikolova; Steve Quiros; Steffen C Naumann; Olivia Kiedron; Małgorzata Z Zdzienicka; Bernd Kaina
Journal:  DNA Repair (Amst)       Date:  2008-10-21

10.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.

Authors:  W K Yung; R E Albright; J Olson; R Fredericks; K Fink; M D Prados; M Brada; A Spence; R J Hohl; W Shapiro; M Glantz; H Greenberg; R G Selker; N A Vick; R Rampling; H Friedman; P Phillips; J Bruner; N Yue; D Osoba; S Zaknoen; V A Levin
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

View more
  12 in total

1.  DNA ligase IV is a potential molecular target in ACNU sensitivity.

Authors:  Natsuko Kondo; Akihisa Takahashi; Eiichiro Mori; Taichi Noda; Xiaoming Su; Ken Ohnishi; Peter J McKinnon; Toshisuke Sakaki; Hiroyuki Nakase; Koji Ono; Takeo Ohnishi
Journal:  Cancer Sci       Date:  2010-04-10       Impact factor: 6.716

2.  Blood-based DNA methylation of DNA repair genes in the non-homologous end-joining (NEHJ) pathway in patient with glioma.

Authors:  Chengcheng Zhou; Hailiang Tang; Jian Yu; Dongxiao Zhuang; Haishi Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 3.  Clinically Applicable Inhibitors Impacting Genome Stability.

Authors:  Anu Prakash; Juan F Garcia-Moreno; James A L Brown; Emer Bourke
Journal:  Molecules       Date:  2018-05-13       Impact factor: 4.411

4.  Ovarian cancer and DNA repair: DNA ligase IV as a potential key.

Authors:  Joana Assis; Deolinda Pereira; Rui Medeiros
Journal:  World J Clin Oncol       Date:  2013-02-10

5.  DNA damage induced by alkylating agents and repair pathways.

Authors:  Natsuko Kondo; Akihisa Takahashi; Koji Ono; Takeo Ohnishi
Journal:  J Nucleic Acids       Date:  2010-11-21

6.  Identification of novel hypoxia response genes in human glioma cell line a172.

Authors:  Fatemeh Baghbani; Reza Raoofian; Mohammad Hasanzadeh Nazarabadi; Tayebeh Hamzehloei; Mohammad Soukhtanloo; Mansur Heidari; Seyed Morteza Afsharzadeh; Sahar Shekouhi; Fahimeh Moradi; Abdol-Azim Sarli; Javad Zavar-Reza; Majid Mojarrad
Journal:  Iran J Basic Med Sci       Date:  2013-05       Impact factor: 2.699

Review 7.  Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma.

Authors:  Laura Annovazzi; Marta Mellai; Davide Schiffer
Journal:  Cancers (Basel)       Date:  2017-05-26       Impact factor: 6.639

8.  Downregulation of both mismatch repair and non-homologous end-joining pathways in hypoxic brain tumour cell lines.

Authors:  Sophie Cowman; Barry Pizer; Violaine Sée
Journal:  PeerJ       Date:  2021-04-30       Impact factor: 2.984

9.  FANCD1/BRCA2 plays predominant role in the repair of DNA damage induced by ACNU or TMZ.

Authors:  Natsuko Kondo; Akihisa Takahashi; Eiichiro Mori; Taichi Noda; Małgorzata Z Zdzienicka; Larry H Thompson; Thomas Helleday; Minoru Suzuki; Yuko Kinashi; Shinichiro Masunaga; Koji Ono; Masatoshi Hasegawa; Takeo Ohnishi
Journal:  PLoS One       Date:  2011-05-09       Impact factor: 3.240

Review 10.  Inhibition of DNA Repair in Cancer Therapy: Toward a Multi-Target Approach.

Authors:  Samuele Lodovichi; Tiziana Cervelli; Achille Pellicioli; Alvaro Galli
Journal:  Int J Mol Sci       Date:  2020-09-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.